--Includes Extensive Data Showing that CM-101, Chemomab's
CCL24-Neutralizing Antibody, Interrupts the
Fibro-Inflammatory Processes that Lead to PSC--
TEL
AVIV, Israel, June 28,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company
developing innovative therapeutics to treat rare fibro-inflammatory
diseases with high unmet need, today announced the publication of a
peer-reviewed research article describing how CCL24 is a key driver
of the fibrotic and inflammatory disease processes that result in
primary sclerosing cholangitis (PSC), a rare disease of the bile
ducts that has no FDA-approved treatments and is often fatal. The
publication also includes preclinical studies showing that CM-101,
Chemomab's CCL24-neutralizing antibody, is effective in
interrupting these fibro-inflammatory processes and could
potentially improve patient outcomes. CM-101 is currently in a
Phase 2 trial for the treatment of PSC. The research article,
CCL24 regulates biliary inflammation and fibrosis in primary
sclerosing cholangitis, was published in the June edition of
JCI Insight.1
"The comprehensive data presented in this publication was
produced through collaborations with prominent academic groups in
the field and strongly supports the key role of CCL24 in driving
the self-perpetuating fibrosis and inflammation that block the bile
ducts, resulting in the severe liver damage found in PSC," said
Adi Mor, PhD, lead author and CEO
and CSO of Chemomab. "We developed our first-in-class
CCL24-neutralizing antibody, CM-101, specifically to interrupt this
cycle and stop disease progression in PSC and other
fibro-inflammatory conditions. Publication of this manuscript in a
respected peer-reviewed journal is the latest in a series of
positive developments we view as supportive of our PSC clinical
trial that is expected to produce topline results next year."
The publication describes the role of CCL24 in PSC and
highlights the potential therapeutic effect of blocking CCL24. The
authors report a wide range of studies confirming the relationship
between elevated CCL24 expression and pro-fibrotic and
pro-inflammatory processes, noting that CCL24 expression induces
the activity of multiple cell types that are highly associated with
fibrotic disease pathogenesis.
Studies reported in the publication utilized samples from
patients with PSC and unveiled novel findings that establish, for
the first time, the role of CCL24 within the crosstalk between
immune cells, fibroblasts and cholangiocytes, which, together
regulate the biliary damage seen in PSC.
Importantly, inhibition of CCL24 with CM-101 demonstrated a
significant attenuation of key fibrotic and inflammatory processes,
specifically evident in the damaged biliary area of the liver. The
authors conclude that taken together, these data further reinforce
the therapeutic potential of blocking CCL24 with CM-101 to reduce
liver inflammation, fibrosis and cholestasis in PSC patients.
Douglas Thorburn, MD, is a
co-author of the review and Professor of Hepatology in the
Institute of Liver and Digestive Health at UCL and Divisional
Medical Director for the Liver and Digestive Health Division
at the Royal Free London NHS Trust. He is also the Principal
Investigator for the CM-101 Phase 2 PSC trial. Dr. Thorburn
commented, "The research article found that CCL24 is overexpressed
in the livers of PSC patients and is localized in those areas and
cell types that drive the disease. These data add to the growing
evidence identifying CCL24 as a regulator and mediator of
cholestatic, inflammatory and fibrotic activity. Given the central
role of CCL24, neutralization with CM-101 could prove to be an
effective strategy to nullify this destructive cascade in PSC and
other fibrotic diseases. As a clinician who sees first-hand the
burden of PSC patients, I am pleased to support the CM-101 Phase 2
PSC trial and look forward to the clinical results targeted for
next year."
The research article is posted on the Chemomab website at
www.chemomab.com/r-d/.
1JCI Insight. 2023;8(12):e162270.
https://doi.org/10.1172/jci.insight.162270
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing
innovative therapeutics for fibro-inflammatory diseases with high
unmet need. Based on the unique and pivotal role of CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies, CM-101 appears safe, with the
potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has reported encouraging
results from three clinical trials of CM-101, including a Phase 2
liver fibrosis trial in NASH patients and an investigator-initiated
study in patients with severe lung injury. A Phase 2 trial in
primary sclerosing cholangitis patients is ongoing, with topline
data expected in the latter part of 2024. For more information
about Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
Company's cash position and expectations regarding its ability to
achieve the topline data readout from the Phase 2 primary
sclerosing cholangitis (PSC) trial of CM-101 with its current cash;
the nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including those found under the caption "Risk Factors" and
elsewhere in Chemomab's filings and reports with the SEC. Chemomab
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Chemomab's expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based, except as
required by law.
Contacts:
Media and
Investors: Barbara
Lindheim
Consulting Vice President, Investor &
Public Relations, Strategic Communications Phone: +1 917-355-9234 barbara.lindheim@chemomab.com
|
Investor
Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 917-734-7387
ir@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-announces-publication-in-jci-insight-demonstrating-key-role-of-ccl24-in-primary-sclerosing-cholangitis-301865386.html
SOURCE Chemomab Therapeutics, Ltd.